Join to access to all OVN content. Join for Free
How Information is Consumed
Medical Science Liaisons Andrew Fariello AstraZeneca data sharing technological advancements

How Information is Consumed


Share This Article


Summary

In this episode, Tom Caravela is joined by Andrew Fariello from AstraZeneca to explore the evolving landscape of Medical Science Liaisons (MSLs) in the context of data sharing and technological advancements. Andrew shares his career journey and insights into the growing importance of surveillance networks and real-world data, especially following the pandemic. The discussion delves into adapting MSL strategies to handle information overload while integrating patient perspectives into medical strategies. Andrew emphasizes the critical role of MSLs, highlighting advancements in engagement and innovative tools. The episode concludes with advice for MSLs navigating scientific developments and a call to action for listeners.

Today’s guest is Andrew Fariello, VP Global Medical Affairs, Head Medical Excellence, Oncology who discusses trends in information/data consumption and what MSLs can do for greater impact

We learn….

๐Ÿ‘‰ How data is being shared as well as how it is being consumed
๐Ÿ‘‰ What he means by the term “instantaneous Information”
๐Ÿ‘‰ What role MSLs play in patient care and patient identification 
๐Ÿ‘‰ How the MSL approach may need to change
๐Ÿ‘‰ Areas of improvement for MSLs in KOL engagement

Click for Source
Medical Science Liaisons, Andrew Fariello, AstraZeneca, data sharing, technological advancements

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%โ€‹
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%โ€‹

Explore OVN